新辅助化疗对乳腺癌患者ER、PR、Her2表达的影响  

Effect of neoadjuvant chemotherapy on the expression of estrogen receptor(ER),progesterone receptor(PR),and Her2 in breast carcinima

作　　者：吴建忠[1] 陈琳[2] 王莎飞 黄维贤[1] 

机构地区：[1]吴江市第一人民医院肿瘤外科,江苏吴江215200 [2]江苏省人民医院乳腺中心,江苏南京210000

出　　处：《海南医学》2013年第24期3654-3656,共3页Hainan Medical Journal

摘　　要：目的对比新辅助化疗前后雌激素受体(ER)、孕激素受体(PR)、人表皮生长因子受体2(Her2)的改变,评估化疗对受体的影响。方法检测54例乳腺癌患者化疗前后ER、PR、Her2的状态。结果 54例患者化疗前ER阳性率为48.1%,化疗后阳性率为44.4%(P=0.7);化疗前PR阳性率为40.1%,化疗后阳性率为22.2%(P=0.038);化疗前Her2阳性表达为63%,化疗后阳性表达为61%(P=0.843)。结论新辅助化疗对ER、Her2表达影响较小,但经新辅助化疗后PR表达率较治疗前明显下降,需进一步研究PR状态转阴的临床意义。Objective To compare immunohistochemical （IHC） profiles （ER, PR, Her2） of breast cancer be- fore and after neoadjuvant chemotherapy and to assess the subsequent effects on hormone receptor status. Methods Ex- pressions of ER, PR, Her2 of 54 patients with breast cancer were measured before and after neoadjuvant chemotherapy.Results Of the 54 carcinomas, there were 48.1% positivity for ER pre-neoadjuvant therapy and 44.4% positivity for- post-treatment （P=0.7）, 40.1% positivity for PR pre-neoadjuvant therapy and 22.2% positivity for post-treatment （P=0.038）, and 63% positivity for HER2 IHC pre-treatment and 61% positivity for post-treatment （P=0.843）. Conclusion Neoadju- vant chemotherapy has no effect on the profiles for ER, Her2 IHC in primary breast carcinomas, and further investigation is warranted to assess reproducibility of technique and investigate clinical implications of significant loss of PR status.

关 键 词：ER PR Her2 新辅助化疗 免疫组化 

分 类 号：R737.9[医药卫生—肿瘤]